For Research Use Only. Not for Human Consumption.
Recorded market$63.67Recorded exact-size market estimate: 63.67 USD for one 10 mg container (6.366700 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$86.89Member price$78.20No member savings vs. this market reference
Thymosin beta-4 peptide for cell-migration research.
Exact-size price research
Supplier observation dates: Oct 11, 2026 UTC. This reference uses recorded prices for the same 10 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$7.82/mg
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 04:31 UTC. 10 mg per vial (catalog label).
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Luxe Peptides Oct 11, 2026 UTC | One 10 mg container; 65.00 USD | $6.50/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Apex Peptide Supply Oct 11, 2026 UTC | One 10 mg container; 69.99 USD | $7.00/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Liberty Peptides Oct 11, 2026 UTC | One 10 mg container; 41.60 USD | $4.16/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Pepta Labs Oct 11, 2026 UTC | One 10 mg container; 56.73 USD | $5.67/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| O Peptides Oct 11, 2026 UTC | One 10 mg container; 95.00 USD | $9.50/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| SwissChems Oct 11, 2026 UTC | One 10 mg container; 42.36 USD | $4.24/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Biotech Compounds Oct 11, 2026 UTC | One 10 mg container; 32.99 USD | $3.30/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Biopeptitech Oct 11, 2026 UTC | One 10 mg container; 45.00 USD | $4.50/mg | lyophilized powder; in stock Price observation; no COA authentication is implied by inclusion. |
| Core Peptides Oct 11, 2026 UTC | One 10 mg container; 140.00 USD | $14.00/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Real Peptides Oct 11, 2026 UTC | One 10 mg container; 48.00 USD | $4.80/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “TB-500 (Thymosin Beta-4) | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/tb-500-thymosin-beta-4/ Accessed [your access date].
Source page: https://peptideserum.com/product/tb-500-thymosin-beta-4/
A synthetic version of the actin-binding peptide thymosin beta-4, studied in laboratory models of cell migration, angiogenesis, and tissue repair.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
TB-500 requires exact identity checking. Analytical papers identify an acetylated seven-residue thymosin beta-4 fragment; full-length thymosin beta-4 studies do not automatically apply to that fragment.
The identified fragment is Ac-LKKTETQ, corresponding to residues 17–23 of thymosin beta-4. Full-length thymosin beta-4 is a different material.
A seller may use TB-500 inconsistently. Neither the short name nor a paper about full-length beta-4 establishes the composition of the product offered.
The directly matched fragment literature reviewed here is largely analytical and preclinical. It establishes identity and metabolism in particular experiments, not successful human tendon or muscle repair. Studies of full-length beta-4, engineered tandem proteins or delivery systems must be labeled separately.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Identification of acetylated thymosin beta-4 fragment in TB-500
Chemical identification and analytical-method work Reading scope: PubMed abstract |
The investigators identified Ac-LKKTETQ in the examined TB-500 preparation and characterized an analytical approach. | This identifies the studied material, not every product using the name or any clinical benefit. |
| TB-500 metabolites and fibroblast wound-healing assays
In-vitro systems, rat metabolism and fibroblast experiments Reading scope: PubMed abstract |
The authors reported that a particular metabolite, rather than the parent fragment, showed significant wound-healing activity in their assay. | An in-vitro wound assay and rat metabolite profile do not establish healing in patients. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
Detecting a peptide after administration tells researchers about exposure. It does not show that an injury healed faster or that treatment was safe.
A report on full-length beta-4 can inform a related biological question, but sequence, metabolism and formulation differences prevent silently transferring the outcome to the acetylated fragment.
FDA’s current page places the beta-4 fragment among nominations withdrawn by nominators and describes limited human safety information and potential route-dependent immunogenicity concerns. Withdrawal from that nomination category is not product approval or evidence of safety.
Do not apply full-length beta-4 exposure schedules or animal fragment doses to an unspecified TB-500 product. Parent compound and metabolite concentrations also describe different analytes.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Require the sequence, acetylation status and expected molecular mass. The report must distinguish full-length beta-4 from Ac-LKKTETQ and identify which one was measured.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. The analytical papers summarized here identify the shorter acetylated fragment. The actual sequence on a product record must settle the question.
No. It is a narrow preclinical result involving a particular assay and does not establish a human injury outcome.
No. The cited change concerns withdrawal of a compounding nomination, not approval of a drug product.
This companion to the TB-500 research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
Do not apply full-length beta-4 exposure schedules or animal fragment doses to an unspecified TB-500 product. Parent compound and metabolite concentrations also describe different analytes.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.